Detalhe da pesquisa
1.
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody.
Am J Transplant
; 20(2): 463-473, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31647605
2.
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.
J Clin Neurosci
; 119: 76-84, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37988976
3.
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.
Lancet Rheumatol
; 2(3): e142-e152, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38263652